Related posts
Hot Meta, hot jobs reportThis summary was created by AI, based on 1 opinions in the last 12 months.
Edwards Lifesciences Corp (EW-N) is experiencing a significant downturn in its stock performance, currently down 30%, which marks the most substantial single-day decline since the year 2000. This sharp drop highlights the market's sensitivity to earnings misses within a context where aggregate valuations remain notably high. Despite the decline, the stock still trades at a multiple of 25 times its earnings after the drop, suggesting that investors might still hold some long-term confidence in its fundamentals. The heavy punishment reflects a broader market trend where companies facing earnings challenges are valued strictly, as the high multiples create an environment where poor performance leads to drastic consequences for stock prices. Thus, while the market reacts harshly to disappointing results, the long-term outlook may warrant further evaluation.
The interesting is that it's still at 25x post-drop. You're seeing earnings misses get punished because the aggregate multiple they trade at is still on the high end.
That had a terrible quarter. They must do better.
Reported a solid quarter and guidance in last April. Is up 20% YTD, but has more room to run. He's bullish medical devices.
He has owned IRTC-O in the past. It is in the medical device space and has equipment that looks for heart arrhythmia and loads the data to the cloud. The market has not yet said this stock has taken a positive turn yet. Earnings are growing and it is growing into its share price. He wants to see it break above $85-$87 before getting back in. He would prefer holding EW-N
When it came down to his model price it was the only buying opportunity there was in the last eight years. He loves the company. Model price is $99.94, a 30% premium that it is trading at. He can only wish for a pull back.
Trans-catheter aortic valve replacement is their business, a best in class valve that's been taken up widely in hospitals around the world. This market will double in three years, and they are the big player. (Analysts' target of $142.80)
Valve replacement. They have trans catheter valve replacements. It is done in the least invasive way that the medical space has come up with. It is all very positive. They are well placed in a growing part of the healthcare market. It is expected to double by 2021. (Analysts’ target: $142.).
Very focused on cardiovascular and ICU. The great thing about this is that the demand is very inelastic, so you get the unit demand independent of the economic cycle, a good solid demand. Also, they are innovators and have good research and good product flow on their own and have been smart acquirers.
Edwards Lifesciences Corp is a American stock, trading under the symbol EW-N on the New York Stock Exchange (EW). It is usually referred to as NYSE:EW or EW-N
In the last year, there was no coverage of Edwards Lifesciences Corp published on Stockchase.
Edwards Lifesciences Corp was recommended as a Top Pick by on . Read the latest stock experts ratings for Edwards Lifesciences Corp.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
0 stock analysts on Stockchase covered Edwards Lifesciences Corp In the last year. It is a trending stock that is worth watching.
On 2025-02-17, Edwards Lifesciences Corp (EW-N) stock closed at a price of $76.18.